Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic ...
TEM is integrating externally developed AI pathology into its ecosystem to improve risk prediction and personalize prostate ...
Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new ...
When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...
Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with ...
A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.
For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...
These results correspond to an 80% reduction in the risk of death among patients surviving beyond five years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results